Loading organizations...
Key people at Amira Pharmaceuticals.
Amira Pharmaceuticals is a San Diego, California-based biotechnology company that discovers and develops small-molecule drugs targeting inflammatory and fibrotic diseases. The organization focuses on modulating bioactive lipids and biological pathways, such as leukotriene and lysophosphatidic acid receptors, to treat conditions including asthma and idiopathic pulmonary fibrosis. Prior to its acquisition, the enterprise successfully raised $40 million in venture capital funding from lead investors including Versant Ventures and Novo A/S. The firm also formed strategic research alliances with major pharmaceutical corporations like Roche to advance its early clinical pipeline. In 2011, Bristol-Myers Squibb acquired the business for $325 million in upfront cash and up to $150 million in milestone payments, valuing the transaction at a maximum of $475 million. Amira Pharmaceuticals was originally founded in 2005 by Peppi Prasit, Jilly Evans, and John Hutchinson.
Amira Pharmaceuticals was a small molecule pharmaceutical company specializing in the discovery and early development of novel drugs targeting inflammatory and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis, asthma, and chronic obstructive pulmonary disease (COPD).[1][2][3] Headquartered in San Diego, California, it leveraged insights into bioactive lipid pathways to advance compounds like AM152 (an LPA1 receptor antagonist) through Phase I clinical studies, serving unmet needs in respiratory, cardiovascular, and fibrotic conditions.[1][3][4] With 13-16 employees and $10.4 million in annual revenue by 2025, the company raised $40 million before being acquired, marking its growth in biotech innovation.[1][2]
Founded in 2005 in San Diego, Amira Pharmaceuticals emerged from expertise in bioactive lipid signaling pathways that regulate inflammatory and fibrotic processes.[1][2][3] The team combined big pharma rigor with startup agility to develop small molecule drugs, securing early partnerships like one with GlaxoSmithKline for FLAP inhibitors in respiratory and cardiovascular diseases.[3] Key milestones included advancing multiple candidates—such as AM152, AM095, AM966 (LPAR1 antagonists for fibrosis), AM432 (CRTH2 for inflammation), AM156 (PGD2 receptor for COPD), and AM679 (FLAP for asthma)—into clinical or preclinical stages, culminating in its 2011 acquisition by Bristol-Myers Squibb to bolster their fibrosis pipeline.[2][3][4]
Amira rode the early 2000s wave of lipid signaling research in biotech, targeting fibrotic diseases amid rising recognition of unmet needs in IPF and scleroderma—conditions with limited treatments.[3][4] Its timing aligned with big pharma's "string of pearls" acquisitions to fill pipeline gaps in inflammation and fibrosis, influencing San Diego's biotech cluster by validating small-molecule discovery models.[2][3] Market forces like advancing Phase I/II assets (e.g., LPA1 antagonists) fueled its appeal, contributing to ecosystem shifts toward targeted therapies now central to respiratory and fibrotic drug development.[1][3][4]
Post-2011 acquisition, Amira's assets integrated into Bristol-Myers Squibb's pipeline, with programs like AM152 advancing toward Phase II for fibrosis, though many (e.g., AM095, AM966) later discontinued.[3][4] Trends in lipid pathway modulators and fibrosis therapies—boosted by AI-driven discovery and precision medicine—could revive similar approaches, evolving Amira's legacy through BMS successors or spinouts. Its story underscores how nimble biotechs shape big pharma innovation, tying back to its origins as a San Diego pioneer in unmet disease spaces.[2][3]
Key people at Amira Pharmaceuticals.
